Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicenter, Randomized Controlled Phase II Study to Evaluate the Efficacy and Safety of Salvage Preoperative PD-1 Inhibitor Combined with Chemotherapy Neoadjuvant Therapy in Recurrent and Metastatic Laryngeal and Hypopharyngeal Squamous Cell Carcinoma

NCT06793761 is registered in ClinicalTrials.gov with Beijing Tongren Hospital as lead sponsor.

NCT NCT06793761
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06793761 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicenter, Randomized Controlled Phase II Study to Evaluate the Efficacy and Safety of Salvage Preoperative PD-1 Inhibitor Combined with Chemotherapy Neoadjuvant Therapy in Recurrent and Metastatic Laryngeal and Hypopharyngeal Squamous Cell Carcinoma
Lead sponsor
Beijing Tongren Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
February 1, 2025
Completion date
December 31, 2028
Enrollment
260 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer